Cognitive Effects of Nimodipine in Patients With Schizophrenia
NCT ID: NCT03671525
Last Updated: 2023-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
18 participants
INTERVENTIONAL
2018-10-05
2023-05-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
NCT01555697
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
NCT00373672
Effects of Galantamine on Cognition
NCT01100775
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818
Modafinil Effects on Cognition in Schizophrenia Patients
NCT00711464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nimodipine
One 60mg capsule of nimodipine on first or second study visit
Nimodipine
Subject will receive two 30mg capsules of nimodipine during study visit.
Placebo
One placebo capsule on first or second study visit
Placebo oral capsule
Two coconut oil capsules that mimic the size and color of the nimodipine capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nimodipine
Subject will receive two 30mg capsules of nimodipine during study visit.
Placebo oral capsule
Two coconut oil capsules that mimic the size and color of the nimodipine capsules
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* uncontrolled medical disorder
* current or past hypotension
* head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma
* positive pregnancy test, or currently breast feeding
* having an adverse reaction to nimodipine, or other calcium channel blocker
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristin Bigos, PhD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Johns Hopkins University
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00168634
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.